Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Marcela Cortés-Jofré, Mikel Rueda-Etxebarria, Emeline Orillard, Elena Jimenez Tejero, José-Ramón Rueda
BACKGROUND: New strategies in immunotherapy with specific antigens that trigger an anti-tumour immune response in people with lung cancer open the possibility of developing therapeutic vaccines aimed at boosting the adaptive immune response against cancer cells. OBJECTIVES: To evaluate the effectiveness and safety of different types of therapeutic vaccines for people with advanced non-small cell lung cancer. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, Wanfang Data, and China Journal Net (CNKI) up to 22 August 2023...
March 12, 2024: Cochrane Database of Systematic Reviews
#22
JOURNAL ARTICLE
Nahid Zareian, Oleg Eremin, Hardev Pandha, Richard Baird, Vineet Kwatra, Gabriel Funingana, Chandan Verma, Desmond Choy, Steven Hargreaves, Pejvak Moghimi, Adrian Shepherd, Dileep N Lobo, Jennifer Eremin, Farzin Farzaneh, Shahram Kordasti, James Spicer
The presence of inhibitory immune cells and difficulty in generating activated effector T cells remain obstacles to development of effective cancer vaccines. We designed a vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression. This Phase 1 trial combined an hTERT-derived 7-peptide library, selected to ensure presentation by both HLA class-I and class-II in 90% of patients, with oral low-dose cyclophosphamide (to modulate Tregs) and the COX2 inhibitor celecoxib...
2024: Experimental Biology and Medicine
#23
JOURNAL ARTICLE
Nadja Schöne, Marcel Kemper, Kerstin Menck, Georg Evers, Carolin Krekeler, Arik Bernard Schulze, Georg Lenz, Eva Wardelmann, Claudia Binder, Annalen Bleckmann
Immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC). High expression of tissue PD-L1 (tPD-L1) is currently the only approved biomarker for predicting treatment response. However, even tPD-L1 low (1-49%) and absent (<1%) patients might benefit from immunotherapy but, to date, there is no reliable biomarker, that can predict response in this particular patient subgroup. This study aimed to test whether tumour-associated extracellular vesicles (EVs) could fill this gap...
March 2024: Journal of Extracellular Vesicles
#24
JOURNAL ARTICLE
Kunze Yu, Xing Fang
Colorectal cancer is a common malignant digestive tract tumour with high morbidity and mortality. Early detection, treatment and diagnosis are crucial for preventing and treating colorectal cancer, which develops through multi-stage accumulation and gene participation, affecting tumour marker levels. Chronic wounds can lead to the development of certain cancers, such as colorectal cancer. The prolonged inflammation and tissue repair caused by chronic wounds can trigger cellular changes, potentially promoting cancerous cell growth in the colon...
March 2024: International Wound Journal
#25
JOURNAL ARTICLE
Ke Xu, Hao Wang, Yu-Xia Zou, Huan-Huan Zhang, Yue-Nan Wang, Xue-Ru Ren, Han-Qi Wang, Ye-Hong Xu, Jia-Jun Li, Hao Tang, Cheng He, Song Wei, Tian Tian, Lai-Lin Li, Hui Zhou, Lin-Juan Xu, Jing-Wen Fang, Chuang Guo, Jia-Xuan Yang, You-Yang Zhou, Zhi-Hong Zhang, Yue-Yin Pan
BACKGROUND: Bone or brain metastases may develop in 20-40% of individuals with late-stage non-small-cell lung cancer (NSCLC), resulting in a median overall survival of only 4-6 months. However, the primary lung cancer tissue's distinctions between bone, brain and intrapulmonary metastases of NSCLC at the single-cell level have not been underexplored. METHODS: We conducted a comprehensive analysis of 14 tissue biopsy samples obtained from treatment-naïve advanced NSCLC patients with bone (n = 4), brain (n = 6) or intrapulmonary (n = 4) metastasis using single-cell sequencing originating from the lungs...
March 2024: Clinical and Translational Medicine
#26
JOURNAL ARTICLE
Siyang Wang, Xiao Bao, Feixing Yang, Hongcheng Shi
OBJECTIVES: This study aimed to determine the predictive factors of lymph node metastases in clinical T0-T1c stage non-small-cell lung cancers, so as to help making surgical strategy. METHODS: From January 2016 to December 2017, patients with clinical T0-T1c stage non-small-cell lung cancers were retrospectively reviewed. We elucidated the lymph node metastatic incidence and distribution according to the primary tumour radiographic findings and maximal standard uptake values (SUVmax), and extracted the associated clinicopathological factors...
March 1, 2024: European Journal of Cardio-thoracic Surgery
#27
JOURNAL ARTICLE
Hua-Chuan Song, Hang-Cheng Zhou, Ping Gu, Bing Bao, Quan Sun, Tian-Ming Mei, Wei Cui, Kang Yao, Huan-Zhang Yao, Shen-Yu Zhang, Yong-Shuai Wang, Rui-Peng Song, Ji-Zhou Wang
BACKGROUND: Colorectal cancer is the third most prevalent malignancy globally and ranks second in cancer-related mortality, with the liver being the primary organ of metastasis. Preoperative chemotherapy is widely recommended for initially or potentially resectable colorectal liver metastases (CRLMs). Tumour pathological response serves as the most important and intuitive indicator for assessing the efficacy of chemotherapy. However, the postoperative pathological results reveal that a considerable number of patients exhibit a poor response to preoperative chemotherapy...
February 15, 2024: World Journal of Gastrointestinal Oncology
#28
JOURNAL ARTICLE
Fiza Mushtaq, Haneen Kamran
No abstract text is available yet for this article.
February 2024: JPMA. the Journal of the Pakistan Medical Association
#29
JOURNAL ARTICLE
Muhammad Waqas, Tanzil Sajid, Mairah Razi
Prostate carcinoma is the most common malignancy in males and the second most common cause of mortality. Initially, metastatic prostate cancers tend to involve bones, but these tumours can involve any system. Gallium-68 prostate specific membrane antigen (PSMA) positron emission computed tomography (PET-CT) scan is indicated in prostate cancer patients if PSA levels are raised, and CT and bone scans are inconclusive. Metastatic penile involvement is a rare phenomenon. We present a case of prostate cancer with foci of PSMA uptake in the penile region...
February 2024: JPMA. the Journal of the Pakistan Medical Association
#30
JOURNAL ARTICLE
Kaifang Liu, Yunfeng Liao, Pu Li, Jing Shi
OBJECTIVES: To determine the clinical significance of Ro52 protein/tripartite motif-containing 21 antibody and specific antinuclear antibody patterns using indirect immunofluorescence technique. METHODS: The retrospective study was conducted at the clinical laboratory of the First Affiliated Hospital of Chongqing Medical University, China, and comprised data from January 2017 to December 2021 of patients who underwent antinuclear antibody and anti-extractable nuclear antigen antibody detection...
February 2024: JPMA. the Journal of the Pakistan Medical Association
#31
JOURNAL ARTICLE
A P Wiegmans, E Ivanova, V Y Naei, J Monkman, J Fletcher, W Mullally, M E Warkiani, K O'Byrne, A Kulasinghe
High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells...
February 28, 2024: Clinical & Experimental Metastasis
#32
Or-Yam Revach, Angelina M Cicerchia, Ofir Shorer, Boryana Petrova, Seth Anderson, Josh Park, Lee Chen, Arnav Mehta, Samuel J Wright, Niamh McNamee, Aya Tal-Mason, Giulia Cattaneo, Payal Tiwari, Hongyan Xie, Johanna M Sweere, Li-Chun Cheng, Natalia Sigal, Elizabeth Enrico, Marisa Miljkovic, Shane A Evans, Ngan Nguyen, Mark E Whidden, Ramji Srinivasan, Matthew H Spitzer, Yi Sun, Tatyana Sharova, Aleigha Lawless, William A Michaud, Martin Q Rasmussen, Jacy Fang, Claire Palin, Feng Chen, Xinhui Wang, Cristina R Ferrone, Donald P Lawrence, Ryan J Sullivan, David Liu, Uma M Sachdeva, Debattama R Sen, Keith T Flaherty, Robert T Manguso, Lloyd Bod, Manolis Kellis, Genevieve M Boland, Keren Yizhak, Jiekun Yang, Naama Kanarek, Moshe Sade-Feldman, Nir Hacohen, Russell W Jenkins
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma. T cell exhaustion, resulting from chronic antigen exposure in the tumour microenvironment, is a major driver of ICB resistance. Here, we show that CD38, an ecto-enzyme involved in nicotinamide adenine dinucleotide (NAD+) catabolism, is highly expressed in exhausted CD8+ T cells in melanoma and is associated with ICB resistance. Tumour-derived CD38hiCD8+ T cells are dysfunctional, characterised by impaired proliferative capacity, effector function, and dysregulated mitochondrial bioenergetics...
February 17, 2024: bioRxiv
#33
Eszter Lakatos, Vinaya Gunasri, Luis Zapata, Jacob Househam, Timon Heide, Nicholas Trahearn, Ottilie Swinyard, Luis Cisneros, Claire Lynn, Maximilian Mossner, Chris Kimberley, Inmaculada Spiteri, George D Cresswell, Gerard Llibre-Palomar, Miriam Mitchison, Carlo C Maley, Marnix Jansen, Manuel Rodriguez-Justo, John Bridgewater, Ann-Marie Baker, Andrea Sottoriva, Trevor A Graham
Immune system control is a major hurdle that cancer evolution must circumvent. The relative timing and evolutionary dynamics of subclones that have escaped immune control remain incompletely characterized, and how immune-mediated selection shapes the epigenome has received little attention. Here, we infer the genome- and epigenome-driven evolutionary dynamics of tumour-immune coevolution within primary colorectal cancers (CRCs). We utilise our existing CRC multi-region multi-omic dataset that we supplement with high-resolution spatially-resolved neoantigen sequencing data and highly multiplexed imaging of the tumour microenvironment (TME)...
February 14, 2024: bioRxiv
#34
JOURNAL ARTICLE
Jiayi Tan, Colt A Egelston, Weihua Guo, Jeremy M Stark, Peter P Lee
BACKGROUND: While mutation-derived neoantigens are well recognized in generating anti-tumour T cell response, increasing evidences highlight the complex association between tumour mutation burden (TMB) and tumour infiltrating lymphocytes (TILs). The exploration of non-TMB determinants of active immune response could improve the prognosis prediction and provide guidance for current immunotherapy. METHODS: The transcriptomic and whole exome sequence data in The Cancer Genome Atlas were used to examine the relationship between TMB and exhausted CD8+ T cells (Tex), as an indicator of tumour antigen-specific T cells across nine major cancer types...
March 2024: EBioMedicine
#35
REVIEW
Rosario Luca Norrito, Maria Grazia Puleo, Chiara Pintus, Maria Grazia Basso, Giuliana Rizzo, Tiziana Di Chiara, Domenico Di Raimondo, Gaspare Parrinello, Antonino Tuttolomondo
Paraneoplastic neurological syndromes (PNSs) are an uncommon complication of cancer, affecting nearby 1/10,000 subjects with a tumour. PNSs can involve all the central and peripheral nervous systems, the muscular system, and the neuromuscular junction, causing extremely variable symptomatology. The diagnosis of the paraneoplastic disease usually precedes the clinical manifestations of cancer, making an immediate recognition of the pathology crucial to obtain a better prognosis. PNSs are autoimmune diseases caused by the expression of common antigens by the tumour and the nervous system...
February 14, 2024: Brain Sciences
#36
JOURNAL ARTICLE
Daniel Johnathan Hughes, Eleni Josephides, Robert O'Shea, Thubeena Manickavasagar, Carolyn Horst, Sarah Hunter, Philippe Tanière, Daisuke Nonaka, Mieke Van Hemelrijck, James Spicer, Vicky Goh, Andrea Bille, Eleni Karapanagiotou, Gary J R Cook
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 expression are closely associated, and studies demonstrate correlation of PD-L1 with glucose metabolism. AIM: The aim of this study was to investigate the association of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([18 F]FDG-PET/CT) metabolic parameters with PD-L1 expression in primary lung tumour and lymph node metastases in resected NSCLC...
February 22, 2024: European Radiology
#37
JOURNAL ARTICLE
Linlin Tang, Cuicui Sun, Wenshan Liu, Haiyan Wu, Chuanhua Ding
Background: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events. This study evaluated the neurotoxicity of ADCs using the FDA Adverse Event Reporting System (FAERS) database. Research design and methods: Data were extracted from the FAERS database for 2004 Q1 to 2022 Q4. We analysed the clinical characteristics of ADC-related neurological adverse events (AEs)...
2024: Frontiers in Pharmacology
#38
JOURNAL ARTICLE
Carolina Cubillos-Zapata, Fernanda Troncoso-Acevedo, Elena Díaz-García, Enrique Alfaro, Carolina Gotera-Rivera, Teresa Pérez-Warnisher, Germán Peces-Barba, Luis M Seijo, Francisco García-Río
BACKGROUND: Intermittent hypoxaemia and obstructive sleep apnoea (OSA) have been linked to lung cancer through as yet unidentified pathophysiological mechanisms. This study evaluates the effect of OSA on serum levels of biomarkers of immunosurveillance, lymphangiogenesis and intrinsic tumour cell aggressiveness in high-risk individuals screened for lung cancer and patients with established lung cancer. METHODS: Serum samples from individuals participating in a lung cancer screening cohort (SAILS study) or with newly diagnosed lung cancer (SAIL study) were analysed...
January 2024: ERJ Open Research
#39
JOURNAL ARTICLE
Roya Eisazadeh, Seyed Ali Mirshahvalad, Gregor Schwieghofer-Zwink, Lukas Hehenwarter, Gundula Rendl, Simon Gampenrieder, Richard Greil, Christian Pirich, Mohsen Beheshti
PURPOSE: To assess the prognostic value of pre-treatment [68 Ga]Ga-PSMA-11 PET/CT and other baseline clinical characteristics in predicting prostate cancer (PCa) patients response to [177 Lu]Lu-PSMA (PSMA-I&T), as well as patient survival. PROCEDURES: In this retrospective study, 81 patients who received [177 Lu]Lu-PSMA-I&T between October 2018 and January 2023 were reviewed. Eligible patients had metastatic castration-resistant PCa, underwent pre-treatment [68 Ga]Ga-PSMA-11 PET/CT, and had serum prostate-specific antigen (PSA) levels available...
February 15, 2024: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
#40
JOURNAL ARTICLE
W Yang, C Qian, J Luo, C Chen, Y Feng, N Dai, X Li, X He, Y Yang, M Li, C Li, D Wang
AIMS: The PCAR study aimed to assess the efficacy and safety of preoperative transcatheter rectal arterial chemoembolisation (TRACE) in patients with locally advanced rectal cancer (LARC). MATERIALS AND METHODS: This was a single-centre, prospective, phase II trial conducted in China. Eligible patients were adults aged 18 years and older with histologically confirmed stage II or III rectal carcinoma and an Eastern Cooperative Oncology Group performance status of 0-1...
January 29, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
